Research programme: sarcoplasmic reticulum calcium ATPase 2a isoform stimulants - Celladon

Drug Profile

Research programme: sarcoplasmic reticulum calcium ATPase 2a isoform stimulants - Celladon

Alternative Names: CDN 1001; CDN 1054; CDN 1234; CDNl 024; CDNl 054; CDNlOOl

Latest Information Update: 26 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celladon
  • Class Small molecules
  • Mechanism of Action Sarcoplasmic reticulum calcium-transporting ATPase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute heart failure; Chronic heart failure

Most Recent Events

  • 26 Feb 2014 Profile reviewed - triggered by NP: 40028. Company no longer appears to be developing small molecules for SERCA2a, only gene therapies for this target and small molecules for SERCA2b - Discontinued profile. Added 9105140 (only MR mentioning small molecule SERCA2a agonists). Added synonyms: CDNl 054, CDNlOOl, CDN 1001, CDNl 234 and CDN 1234 according to patent application WO2010085514 A1 (only source mentioning CDN molecules), more specific MoA, IV RoA, NME, licensing text, additional info to intro. Changed profile name to RP: SERCA2a stimulants from RP: heart failure therapy. All previous information in profile was unreferenced - assumed from Co. website, above sources at least prove that the compounds existed.
  • 28 Sep 2009 Preclinical trials in Acute heart failure in USA (IV)
  • 28 Sep 2009 Preclinical trials in Chronic heart failure in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top